486 related articles for article (PubMed ID: 28004528)
21. Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in ALL (acute lymphoblastic leukemia) cured patients.
Brassesco MS; Camparoto ML; Tone LG; Sakamoto-Hojo ET
Cytogenet Genome Res; 2004; 104(1-4):346-51. PubMed ID: 15162063
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
23. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
24. Hemophagocytosis by leukemic blasts in B lymphoblastic leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1): a case report.
Park JE; Park IJ; Lim YA; Lee WG; Cho SR
Ann Clin Lab Sci; 2013; 43(2):186-9. PubMed ID: 23694795
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia.
Fears S; Vignon C; Bohlander SK; Smith S; Rowley JD; Nucifora G
Genes Chromosomes Cancer; 1996 Oct; 17(2):127-35. PubMed ID: 8913730
[TBL] [Abstract][Full Text] [Related]
26. ETV6/RUNX1 rearrangement identified by RT-PCR without evidence on FISH.
Hahm C; Han SH; Mun YC; Seong CM; Chung WS; Huh J
Acta Haematol; 2014; 132(1):122-4. PubMed ID: 24557455
[No Abstract] [Full Text] [Related]
27. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
[TBL] [Abstract][Full Text] [Related]
28. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
30. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.
Gao YJ; Zhu XH; Yang Y; Wu Y; Lu FJ; Zhai XW; Wang HS
Cancer Genet Cytogenet; 2007 Oct; 178(1):57-60. PubMed ID: 17889709
[TBL] [Abstract][Full Text] [Related]
32. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
33. Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia.
Alpár D; Kajtár B; Kneif M; Jáksó P; László R; Kereskai L; Pajor L
Cancer Genet Cytogenet; 2007 Feb; 173(1):23-30. PubMed ID: 17284366
[TBL] [Abstract][Full Text] [Related]
34. RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children.
Chen D; Camponeschi A; Nordlund J; Marincevic-Zuniga Y; Abrahamsson J; Lönnerholm G; Fogelstrand L; Mårtensson IL
Cancer Med; 2021 Jun; 10(12):3997-4003. PubMed ID: 33987955
[TBL] [Abstract][Full Text] [Related]
35. Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
Mosad E; Hamed HB; Bakry RM; Ezz-Eldin AM; Khalifa NM
J Hematol Oncol; 2008 Oct; 1():17. PubMed ID: 18928518
[TBL] [Abstract][Full Text] [Related]
36. Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with Clinical Parameters and Early Remission.
Aljamaan K; Aljumah TK; Aloraibi S; Absar M; Iqbal Z
Asian Pac J Cancer Prev; 2015; 16(17):7523-7. PubMed ID: 26625756
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
[TBL] [Abstract][Full Text] [Related]
38. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]